Table 2.
Univariate and Multivariate Analysis of OS and RFS in AML with Normal Karyotype.
| End point | Variables | Univariate | Multivariate | ||
|---|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | ||
| OS | |||||
| H-GNA15 | 2.77 (1.33-5.79) | 0.007 | 2.62 (1.25-5.51) | 0.011 | |
| Age≥60 years | 1.74 (0.74-4.07) | 0.205 | |||
| Female | 0.43 (0.21-0.89) | 0.024 | 0.46 (0.22-0.96) | 0.039 | |
| Risk group | |||||
| Low vs High | 0.62 (0.20-1.90) | 0.400 | |||
| Medium vs High | 0.86 (0.40-1.85) | 0.694 | |||
| MRD | 1.00 (0.99-1.03) | 0.676 | |||
| FLT3-ITD+ | 0.76 (0.31-1.87) | 0.553 | |||
| WT1 | 1.00 (0.99-1.02) | 0.660 | |||
| NPM1 | 0.96 (0.33-2.74) | 0.933 | |||
| DNMT3A | 0.86 (0.26-2.86) | 0.810 | |||
| IDH1/2 | 0.82 (0.32-2.16) | 0.693 | |||
| TET2 | 1.36 (0.66-2.81) | 0.399 | |||
| RUNX1 | 3.71 (0.83-16.62) | 0.087 | 2.89 (0.63-13.28) | 0.174 | |
| RFS | |||||
| H-GNA15 | 2.36 (1.01-5.52) | 0.047 | 2.45 (1.04-5.73) | 0.040 | |
| Age≥60 years | 1,51 (0.50-4.53) | 0.466 | |||
| Female | 0.39 (0.17-0.90) | 0.028 | 0.37 (0.16-0.88) | 0.024 | |
| Risk group | |||||
| Low vs High | 0.92 (0.28-3.03) | 0.889 | |||
| Medium vs High | 1.12 (0.44-2.85) | 0.811 | |||
| MRD | 1.01 (0.99-1.03) | 0.412 | |||
| FLT3-ITD+ | 0.90 (0.33-2.45) | 0.838 | |||
| WT1 | 1.01 (0.99-1.03) | 0.555 | |||
| NPM1 | 0.96 (0.28-3.24) | 0.940 | |||
| DNMT3A | 0.73 (0.17-3.13) | 0.670 | |||
| IDH1/2 | 1.10 (0.40-2.97) | 0.864 | |||
| TET2 | 1.25 (0.54-2.92) | 0.603 | |||
| RUNX1 | 2.23 (0.28-17.47) | 0.446 | |||
OS, overall survival; RFS, relapse free survival; H-GNA15, high GNA15 expression; L-GNA15, low GNA15 expression; HR, hazard ratio; CI, confidence interval; MRD, minimal residual disease.